These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46 related articles for article (PubMed ID: 30977836)
1. Response to a letter to the editor, "Studying the incidence of thyroid cancer in Ecuador: 2016-2021". Paz-Cruz E; Cadena-Ullauri S; Guevara-Ramírez P; Ruiz-Pozo VA; Tamayo-Trujillo R; Simancas-Racines D; Zambrano AK Heliyon; 2024 May; 10(10):e30963. PubMed ID: 38803986 [No Abstract] [Full Text] [Related]
2. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771 [TBL] [Abstract][Full Text] [Related]
3. Letter to the Editor: "Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features". Garrahy A; Murphy NP; Byrne MM J Clin Endocrinol Metab; 2019 Sep; 104(9):3624-3625. PubMed ID: 30977837 [No Abstract] [Full Text] [Related]
7. Response to Letter to the Editor: "Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features". Thakar R; Gajewska-Knapik K; Ogilvy-Stuart AL; Chatterjee K; Moran C J Clin Endocrinol Metab; 2019 Sep; 104(9):3626-3627. PubMed ID: 30977836 [No Abstract] [Full Text] [Related]
8. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management. Mahzari M; Arnaout A; Freedman MS Can J Neurol Sci; 2015 Sep; 42(5):284-91. PubMed ID: 25990097 [TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Ruck T; Bittner S; Wiendl H; Meuth SG Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829 [TBL] [Abstract][Full Text] [Related]
10. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL. Kennedy B; Hillmen P Med Oncol; 2002; 19 Suppl():S49-55. PubMed ID: 12180492 [TBL] [Abstract][Full Text] [Related]
11. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Zinzani PL; Corradini P; Gallamini A; Grossi A; Lazzarino M; Marchetti M; Martelli M; Rossi G; Vitolo U Leuk Lymphoma; 2012 May; 53(5):789-95. PubMed ID: 21980956 [TBL] [Abstract][Full Text] [Related]